Pcsa stock.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for cancer patients. CEO George Ng recently issued a letter to shareholders, emphasizing the company's pivot to focus on oncology drug …

Pcsa stock. Things To Know About Pcsa stock.

PCSA Stock Smart Score The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.Jan 18, 2024 ... Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced a reverse stock split with a fixed split ratio of 1-for-20. The stock will begin trading ...The average trading volume of PCSA on May 16, 2024 was 1.48M shares. PCSA) stock’s latest price update. Processa Pharmaceuticals Inc (NASDAQ: PCSA)’s stock price has plunge by -7.34relation to previous closing price of 2.18. Nevertheless, the company has seen a -18.55% plunge in its stock price over the last five trading sessions.Get the latest stock price, quote, news and history of PCSA, a biotechnology company developing drugs for neurodegenerative diseases. See key data, market cap, data …

Processa Pharmaceuticals, Inc. had a return of -66.53% year-to-date (YTD) and -76.87% in the last 12 months. Over the past 10 years, Processa Pharmaceuticals, Inc. had an annualized return of -71.93%, while the S&P 500 had an annualized return of 10.89%, indicating that Processa Pharmaceuticals, Inc. did not perform as well as the …PCSA stock quote, chart and news. Get PCSA's stock price today.

PCSA is unchanged $0.00 from the previous closing price of $0.55 on volume of 537,604 shares. Over the past year the S&P 500 has risen 17.03% while PCSA is lower by -70.59%. PCSA lost -$1.44 per share the over the last 12 months. Click Here to get the full Stock Report for Processa Pharmaceuticals Inc stock.

Bluberries. Pharmaceutical company Processa Pharmaceuticals (NASDAQ:PCSA) said on Thursday that it is set to effect a 1-for-20 reverse stock split to regain compliance with Nasdaq rule.The share ...Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304.The Company’s common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Monday, January 22, 2024. Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Raleigh nc to charleston sc

PCSA Stock Price. -82.28% May 2024 Mar 2024 Jan 2024 Nov 2023 Sep 2023 Jul 2023 0 5 10 15 20. 52 Week Range. 1.40 18.00. Day Range. 2.08 2.19. EPS (FWD) -3.82. PE. - …

PCSA is the ticker symbol for Processa Pharmaceuticals Inc., a biotech company developing treatments for neurodegenerative diseases. The stock price, news, analyst ratings, financials and other data are available on MarketWatch.Trade PCSA with: Price/Earnings ttm 0.00. Earnings Per Share ttm -7.44. Most Recent Earnings $-0.24 on 03/29/24. Latest Earnings Date 05/20/24. Annual Dividend & Yield …Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may...In this article: PCSA. Insiders who bought US$210.6k worth of Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA) stock in the last year recovered part of their losses as the stock rose by 18% last week ...See Processa Pharmaceuticals, Inc. (PCSA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has announced a public offering of 1,555,555 shares of common stock and common warrants, with a combined public offering price of $4.50 per share. The gross proceeds from the offering are expected to be $7.0 million. The common warrants will have an exercise price of $4.50 per share and a term of five years after their original issuance date.View the real-time Processa Pharmaceuticals Inc (NASDAQ PCSA) share price. Assess historical data, charts, technical analysis and contribute in the forum.PCSA Nasdaq Stock Market. PCSA Nasdaq Stock Market. PCSA Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials . News . Ideas Technicals Forecast . PCSA news. Time Symbol Headline Provider. Love in every #TradingView. 60M+ Traders and investors use our platform. #1. Top website in the …Processa Pharmaceuticals Inc stock (PCSA) in USD. 1 PCSA = 2.91 USD. 1 maand. 6 maanden. 1 year. 5 jaar. Processa Pharmaceuticals Inc stock performance at a glance. Check Processa Pharmaceuticals Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. PCSA Stock …Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing ...Price Performance Review of PCSA. On Tuesday, Processa Pharmaceuticals Inc [NASDAQ:PCSA] saw its stock jump 3.81% to $2.18. Over the last five days, the stock has gained 36.25%. Processa Pharmaceuticals Inc shares have fallen nearly -67.42% since the year began. Nevertheless, the stocks have fallen -82.70% over the past one year.PCSA Price Action: According to Benzinga Pro, Processa Pharmaceuticals shares are up 148% at $5.09 at the time of publication. Image: Pete Linforth from Pixabay Market News and Data brought to you ...

PCSA Stock Price. -82.28% May 2024 Mar 2024 Jan 2024 Nov 2023 Sep 2023 Jul 2023 0 5 10 15 20. 52 Week Range. 1.40 18.00. Day Range. 2.08 2.19. EPS (FWD) -3.82. PE. - …According to the announcement, PCSA common stock is slated to begin trading on a reverse stock split-adjusted basis at market opening on Jan. 22, 2024, under the same symbol: PCSA. The intention of the reverse stock split, the announcement noted, is for Processa Pharmaceuticals to regain compliance with the minimum bid price requirement of $1 ...

About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Processa Pharmaceuticals, Inc. Common Stock (PCSA) Pre ...52 Week High Date 10/16/23. 52 Week Low 1.40. 52 Week Low Date 04/16/24. Market Cap 6.197M. Shares Out 2.86M. 10 Day Average Volume 8.03M. Dividend -. Dividend Yield -. Beta 0.58. View today's Processa Pharmaceuticals Inc stock price and latest PCSA news and analysis. Create real-time notifications to follow any changes in the live stock price. ©2024 Processa Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy Disclaimer Sitemap Manage Cookie Preferences. Market Data copyright © 2024 QuoteMedia.Processa Pharmaceuticals, Inc. announces plans to expand the development of NGC-Cap into the treatment of advanced or metastatic breast cancer. The FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design, making the development a more efficient and straightforward path to approval. The expansion into breast cancer represents a larger market than ...Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules. (GlobeNewswire) Jan-04-23 08:30AM. Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.Jan 25, 2024 ... ... stock selection process, how I determine entries/exits, my strategy, and more in my free class Register here: https://www.warriortrading ...PCSA Competitors. $ Market cap P/E ratio $ Price 1d change 52-week range. View Processa Pharmaceuticals, Inc. PCSA stock quote prices, financial information, real-time forecasts, and company news ...Processa Pharmaceuticals stock analysis 2024. View PCSA current price, quote, financial & revenue summaries, forecast, earnings transcripts, and news. ... Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use. Company. About …According to the issued ratings of 3 analysts in the last year, the consensus rating for Processa Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for PCSA. The average twelve-month price prediction for Processa Pharmaceuticals is $8.00 with a high price target of $8.00 and a low price target of $8.00.

Madame x sargent

PROCESSA PHARMACEUTICALS INC (PCSA) US74275C3043 - Common Stock . 1.58 +0.02 (+1.28%) After market: 1.45 -0.13 (-8.23%) Profile . Stock Chart . Technical Analysis . Fundamental Analysis . Analyst Ratings . Estimates . Financials . Ownership . News . Full profile views are only available for registered users, you can see which data is available …

PCSA is a biopharmaceutical company developing drugs for fibrotic diseases. It has a low price, a high uncertainty rating, and no analyst coverage. See its …NASDAQ. 2.090. -0.040. -1.88% After Hours: 2.099 +0.009 +0.44% 16:09 05/10 EDT. OPEN. 2.110. PREV CLOSE. 2.130. HIGH. 2.190. LOW. 2.081. VOLUME. 55.36K. …Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) provides interim analysis from its Phase 1b study of Next Generation Capecitabine (NGC-Cap), showing improved safety and efficacy over capecitabine. Patients received lower doses of NGC-Cap resulting in 5-FU exposure up to 10 times greater than capecitabine, with similar side effect …Processa Pharmaceuticals (NASDAQ:PCSA) stock rallied 25% in morning trading Friday after the company said it plans to expand development of NGC-Cap into breast cancer to provide a “more ...Processa Pharmaceuticals Inc (PCSA) stock has risen 4.99% while the S&P 500 is lower by -0.08% as of 9:46 AM on Monday, Mar 4. PCSA has risen $0.12 from the previous closing price of $2.46 on volume of 7,228 shares. Over the past year the S&P 500 is up 26.79% while PCSA is lower by -80.15%. PCSA lost -$22.82 per share in the over …PCSA has fallen -$0.02 from the previous closing price of $2.34 on volume of 37,450 shares. Over the past year the S&P 500 has risen 20.23% while PCSA has fallen -85.85%. PCSA lost -$22.82 per share the over the last 12 months. Click Here to get the full Stock Report for Processa Pharmaceuticals Inc stock.Processa Pharmaceuticals, Inc. (US:PCSA) has 6 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 6,620 shares.Processa Pharmaceuticals Stock forecast & analyst price target predictions based on 1 analysts offering 12-months price targets for PCSA in the last 3 months.Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304.

52 Week High Date 10/16/23. 52 Week Low 1.40. 52 Week Low Date 04/16/24. Market Cap 6.197M. Shares Out 2.86M. 10 Day Average Volume 8.03M. Dividend -. Dividend Yield -. Beta 0.58.Stock Price Forecast. The 2 analysts with 12-month price forecasts for PCSA stock have an average target of 6.00, with a low estimate of 4.00 and a high estimate of 8.00. The average target predicts an increase of 187.08% from the current stock price of 2.09.Stock analysis for T-Mobile US Inc (PCS:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Instagram:https://instagram. off the 5th HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ( Processa or the Company ), a clinical-stage pharmaceutical company focused on developing the next... Insider Buying: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Director Buys 8,000 Shares of Stock Zolmax • 3 months ago.The Processa Pharmaceuticals stock forecast for tomorrow is $ 2.40, which would represent a 8.31% gain compared to the current price. In the next week, the price of PCSA is expected to increase by 11.71% and hit $ 2.48.. As far as the long-term Processa Pharmaceuticals stock forecast is concerned, here’s what our predictions are currently suggesting (these … encrypted meaning PROCESSA PHARMACEUTICALS INC (PCSA) US74275C3043 - Common Stock . 1.58 +0.02 (+1.28%) After market: 1.45 -0.13 (-8.23%) Profile . Stock Chart . Technical Analysis . Fundamental Analysis . Analyst Ratings . Estimates . Financials . Ownership . News . Full profile views are only available for registered users, you can see which data is available …Mountain. Loading Chart for PCSA. 9/21 12:03 PM. Previous Close 2.1300. Open 2.1100. Bid 2.0500 x 100. Ask 2.1100 x 200. Day's Range 2.0813 - 2.1900. 52 Week Range 1.4000 - 18.0000. Volume... los angeles metro lines Bluberries. Pharmaceutical company Processa Pharmaceuticals (NASDAQ:PCSA) said on Thursday that it is set to effect a 1-for-20 reverse stock split to regain compliance with Nasdaq rule.The share ... flights to hungary Interactive stock price chart for Processa Pharmaceuticals, Inc. (PCSA) with real-time updates, full price history, technical analysis and more.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestig... bright lending phone number Per-Share Earnings, Actuals and Estimates. View the latest Processa Pharmaceuticals Inc. (PCSA) stock price, news, historical charts, analyst ratings and financial information …PCSA Earnings Date and Information. Processa Pharmaceuticals last posted its earnings data on March 29th, 2024. The reported ($0.24) EPS for the quarter. Processa … complete vocal technique See Processa Pharmaceuticals, Inc. (PCSA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. patreon a PCSA is a biopharmaceutical company developing drugs for fibrotic diseases. It has a low price, a high uncertainty rating, and no analyst coverage. See its …Get the latest Processa Pharmaceuticals Inc (PCSA) real-time quote, historical performance, charts, and other financial information to help you make more informed … the summer i tirn pretty The Company’s common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Monday, January 22, 2024. Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304. pdx to austin Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules. (GlobeNewswire) Jan-04-23 08:30AM. Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.Stock Price Forecast. The 2 analysts with 12-month price forecasts for PCSA stock have an average target of 6.00, with a low estimate of 4.00 and a high estimate of 8.00. The average target predicts an increase of 187.08% from the current stock price of 2.09. dns_probe_finished_nxdomain android Stock Price Statistics The stock price has decreased by -83.46% in the last 52 weeks. The beta is 0.53, so PCSA's price volatility has been lower than the market average. history of the world movie The latest Processa Pharmaceuticals stock prices, stock quotes, news, and PCSA history to help you invest and trade smarter. ... Processa Pharmaceuticals Stock Snapshot. 2.31 Bid. 100.00 Bid Size ...Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of ...